[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ischemic-heart-disease-ihd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ischemic-heart-disease-ihd":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,79,109,132,160],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100581757","the-multicenter-stress-cardiac-magnetic-resonance-quantitative-perfusion-imaging-in-the-united-states-study-100581757",false,"NCT06854458","The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study","The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States (SPINS2) Study","SPINS2","Inclusion Criteria:\n\n1. male or female at age 35-85 years,\n2. presence of either of the following sign\u002Fsymptom that led to a referral to stress cardiac magnetic resonance imaging:\n\n   1. chest pain or anginal equivalent, or\n   2. abnormal electrocardiogram with a suspicion of coronary artery disease\n3. Intermediate or high risk of significant coronary disease based on at least 1 of the following conditions:\n\n   a) patient age \\> 45 for male, 50 for female b) Diabetes, hypertension, or hypercholesterolemia: by either history or medical treatment c) family history of premature coronary disease: first degree relative at age \\\u003C= 55 male and \\\u003C=65 female d) history of smoking of \\> 10 packed-years e) post-menopausal state \\>5 years f) any chronic inflammatory conditions d) Body mass index \\> 30 e) Any medical documentation of coronary or peripheral artery disease\n\nExclusion Criteria:\n\n1. Acute myocardial infarction within the past 30 days prior to cardiac magnetic resonance imaging\n2. Confirmed diagnosis of any significant non-coronary cardiac conditions below:\n\n   1. any severe-grade valvular heart disease,\n   2. left ventricular ejection fraction \\\u003C40% from any known non-coronary causes,\n   3. infiltrative cardiomyopathy,\n   4. hypertrophic cardiomyopathy,\n   5. pericardial disease with significant constriction, or\n3. active pregnancy,\n4. any competing conditions leading to an expected survival of \\\u003C 2 years\n5. contraindication to vasodilator (regadenoson or adenosine)\n6. metallic device or object that poses an magnetic resonance imaging safety hazard\n7. metallic device with a high likelihood of non-diagnostic cardiac magnetic resonance images","ALL","35 Years","85 Years",{"count":21,"type":22},1000,"ESTIMATED","INTERVENTIONAL",[25],"NA","This research aims to investigate whether symptoms of chest pain or shortness of breath among the study population are arising due to a heart problem, particularly any reduction of blood flow to the heart muscle from blockages in the coronary blood vessels or inflammation of the heart using cardiac magnetic resonance imaging that measures the amount of blood flow during a stress state meant to simulate vigorous exercise. At present, doctors use standard magnetic resonance imaging pictures of blood flow patterns to treat heart disease. The investigators want to study if detailed blood flow measurements, in addition to the standard blood flow pattern, could diagnose heart disease more accurately and allow more doctors to understand the severity of heart disease. Early research has demonstrated that detailed blood flow measurements may be more accurate in diagnosing heart disease in some patients, but doctors need more information to know how to use these measurements.",[28,29,30],"Ischemic Heart Disease (IHD)","Cardiac Magnetic Resonance Imaging","Myocardial Blood Flow",[30,32,33,34],"Cardiac Magnetic Resonance","Quantitative perfusion","Cardiovascular Outcomes","RECRUITING","2026-06-01",{"date":38,"type":39},"2026-06-03","ACTUAL",{"date":41,"type":39},"2025-06-27",{"date":43,"type":22},"2029-03",{"name":45,"class":46},"Brigham and Women's Hospital","OTHER",12,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100638834","multimodal-magnetic-resonance-imaging-in-cardiovascular-disease-100638834","NCT07617844","Multimodal mAgnetic Resonance imaGIng in Cardiovascular Disease","Multimodal-MRI in Cardiovascular Diseases","MAGIC","Inclusion Criteria:\n\n* Aged 18 years and older, with no gender restrictions.\n\nClinically suspected or confirmed cardiovascular disease (including but not limited to ischemic heart disease, non-ischemic cardiomyopathy, myocarditis, valvular disease, etc.), requiring a cardiac magnetic resonance (CMR) examination to determine the etiology or evaluate myocardial tissue characteristics.\n\nNo contraindications to magnetic resonance examination, and able to cooperate with breath-holding instructions.\n\nVoluntarily participate in this study and sign a written informed consent form.\n\nExclusion Criteria:\n\n* Absolute contraindications: Implantation of non-MRI compatible metallic foreign bodies (e.g., old pacemakers, implantable cardioverter-defibrillators \\[ICD\\], aneurysm clips, etc.).\n\nRelative contraindications: Severe claustrophobia, unable to complete the examination despite communication.\n\nSevere renal insufficiency.\n\nSpecial populations: Pregnant or lactating women.\n\nPresence of severe arrhythmias (e.g., persistent atrial fibrillation) leading to severely impaired magnetic resonance signal acquisition, rendering the image quality inadequate for diagnosis.\n\nPoor expected compliance: Unable to complete follow-up, or deemed unsuitable for enrollment by the investigator for other reasons.","18 Years",{"count":58,"type":22},2000,"3 Years","OBSERVATIONAL","This single-center, prospective, observational cohort study aims to evaluate the clinical application value of multi-modal cardiovascular magnetic resonance (CMR) imaging in patients with cardiovascular diseases (CVD).\n\nWhile traditional imaging methods have limitations in fully evaluating myocardial tissue characteristics, multi-modal CMR offers a comprehensive, non-invasive \"one-stop\" assessment. It can simultaneously evaluate heart structure, function, tissue features (such as fibrosis and edema), and hemodynamics.\n\nThe study plans to enroll patients with suspected or confirmed CVD. Participants will undergo a comprehensive multi-modal CMR scan (including Cine, T1\u002FT2 mapping, Late Gadolinium Enhancement, and 4D flow sequences) as part of their evaluation. By tracking clinical outcomes, the study seeks to establish a standardized imaging assessment system to improve the early detection, accurate diagnosis, risk stratification, and prognostic prediction for various types of cardiovascular diseases.",[63,28,64,65,66],"Cardiovascular Diseases","Cardiomyopathy","Myocarditis","Heart Valve Diseases",[32,68,69],"Magnetic Resonance Imaging","Multimodal Imaging","2026-05-26",{"date":36,"type":39},{"date":73,"type":39},"2026-01-01",{"date":75,"type":22},"2028-12-31",{"name":77,"class":46},"Second Affiliated Hospital, School of Medicine, Zhejiang University",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100636728","online-personalized-psychological-intervention-for-patients-with-heart-disease-and-depression-or-anxiety-my-choice-100636728","NCT07569458","Online Personalized Psychological Intervention for Patients With Heart Disease and Depression or Anxiety (MY-CHOICE)","Online Personalized and Patient-preferred Comprehensive Intervention for Patients With Heart Disease and Depression or Anxiety (MY-CHOICE)","MY-CHOICE","Inclusion Criteria:\n\n* ischemic heart disease (diagnostic codes I20-I25),\n* referred for CR with a positive screen for depression and\u002For anxiety with the Hospital Anxiety and Depression Scale (HADS ≥ 8)\n* access to and ability to use a computer or tablet\n* proficient in the Danish language\n\nExclusion Criteria:\n\n* Severe psychiatric disorder (i.e., borderline disorder, schizophrenia or bipolar disorder) that requires psychiatric care\n* severe cognitive difficulties (e.g., severe brain damage, mental retardation, or dementia) that will prevent patients from participating\n* endorsement of suicidal ideation with suicidal thoughts (purpose designed questions) that cannot be handled in the intervention\n* participation in other intervention studies focused (unless they are clinical studies)\n* seeing a psychologist or mental health professional for the treatment of anxiety and depression\n* not being able or willing to spend 3-4 hours on the intervention each week\n* experiencing significant life stressors that hinder adherence to the MY-CHOICE treatment",{"count":88,"type":22},30,[25],"The goal of this feasibility study is to assess if the personalised online psychological intervention MY-CHOICE is acceptable to adults with ischemic heart disease and anxiety or depression. It will also examine the reasons for drop-out. The main questions the study aims to answer are:\n\nHow many participants complete the intervention and what are the reasons for drop-out. And what are the pre-post change scores on anxiety and depression.\n\nParticipants will:\n\nComplete the MY-CHOICE intervention consisting of 6-12 weeks with online modules on various topics based on individual needs in combination with video- or telephone calls with a therapist (psychologist or a trained master student in Psychology) on a need-to basis.\n\nAnswer a set of questionnaires pre and post intervention. Participate in a brief interview post intervention.",[28,92,93],"Anxiety","Depression",[95,96,97,98],"online intervention","psychological intervention","ischemic heart disease","treatment of anxiety and depression","2026-04-28",{"date":101,"type":39},"2026-05-06",{"date":103,"type":39},"2025-07-04",{"date":105,"type":22},"2026-10",{"name":107,"class":46},"University of Southern Denmark",3,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":131},"100621648","a-clinical-evaluation-of-amj-401-100621648","NCT07373353","A Clinical Evaluation of AMJ-401","AMJ-401 Japan Clinical Trial","Inclusion Criteria\n\n1. Subject must be at least 18 years of age.\n2. Subject or a legally authorized representative must be able to provide written Informed Consent prior to any study related procedure, per site requirements.\n3. Subject must have evidence of myocardial ischemia (e.g., stable angina, silent ischemia, unstable angina, acute myocardial infarction) suitable for elective PCI.\n4. Subject must be an acceptable candidate for coronary artery bypass graft (CABG) surgery.\n5. Subject must be able to take dual antiplatelet therapy (DAPT) for minimum of 12 months following the index procedure and anticoagulants prior\u002Fduring the index procedure, and the subject has no known allergic reaction, hypersensitivity or contraindication to aspirin, clopidogrel, prasugrel, ticagrelor, ticlopidine or heparin.\n6. Female subjects of childbearing potential must not be pregnant\\* at screening and do not plan pregnancy for at least 12 months following the index procedure.\n\n   \\* Female subjects of child-bearing potential must have a negative pregnancy result within 7 days prior to the index procedure.\n7. Female subjects must not be breast-feeding at the time of the screening visit and will not be breast-feeding for at least 12 months following the index procedure.\n8. Subject agrees to not participate in any other investigational or invasive clinical study for a period of 13 months following the index procedure.\n\nExclusion Criteria:\n\n1. Elective surgery planned within 12 months after the procedure that will require general anesthesia or discontinuing either aspirin or P2Y12 inhibitor.\n2. Subject has known hypersensitivity or contraindication to device material and its degradants (everolimus, PLLA, PDLLA, platinum, lactic acid, and lactide) that cannot be adequately pre-medicated.\n3. Subject has a known contrast sensitivity that cannot be adequately pre-medicated.\n4. Subject with known diagnosis of ST-elevation myocardial infarction (STEMI) within 72 hours of the index procedure.\n5. The subject is currently experiencing clinical symptoms consistent with new onset acute myocardial infarction (AMI), such as nitrate-unresponsive prolonged chest pain with ischemic ECG changes.\n6. Subject has an unstable cardiac arrhythmia which is likely to become hemodynamically unstable due to their arrhythmia\n7. Subject has a known left ventricular ejection fraction (LVEF) \\\u003C 30% (LVEF may be obtained at the time of the index procedure prior to subject registration if the value is unknown and the site Investigator believes it is necessary).\n8. The target vessel was treated by PCI within 12 months prior to index procedure.\n9. Prior PCI within the non-target vessel is acceptable if performed anytime \\> 30 days before the index procedure, or between 24 hours and 30 days before the index procedure if successful and uncomplicated.\n10. Subject requires future staged PCI either in target or non-target vessels.\n11. Subject has a malignancy that is not in remission.\n12. Subject is receiving immunosuppressant therapy or has known life-threatening immunosuppressive or life-threatening autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are not included as immunosuppressant therapy, diabetes mellitus is not regarded as autoimmune disease.\n13. Subject has received any solid organ transplants or is on a waiting list for any solid organ transplants.\n14. Subject has previously received or scheduled to receive radiotherapy to coronary artery (brachytherapy), or chest\u002Fmediastinum.\n15. Subject is receiving or will require chronic anticoagulation therapy (e.g., warfarin).\n16. Subject has a platelet count \\\u003C 100,000 cells\u002Fmm3 or \\> 700,000 cells\u002Fmm3.\n17. Subject has documented or suspected cirrhosis of Child-Pugh ≥ Class B.\n18. Subject has known renal insufficiency:\n\n    * Dialysis at the time of screening or\n    * An estimated GFR \\\u003C 30 ml\u002Fmin\u002F1.73m2\n19. Subject has a high risk of bleeding, or;\n\n    * Subject has a history of bleeding diathesis or coagulopathy.\n    * Subject has had a significant gastro-intestinal or significant urinary bleed within the past six months.\n    * Subject has prior intracranial bleed (including severe permanent neurologic deficit that seems to be caused by previous intracranial bleeding).\n    * Subject has known intracranial pathology that may cause intracranial bleeding per investigator assessment (e.g., untreated aneurysm greater than 5 mm, arteriovenous malformation)\n    * Subject will refuse blood transfusions.\n    * Subject is receiving antiplatelet medication other than aspirin or P2Y12 inhibitor for the treatment of another condition and cannot discontinue them\n20. Subject has had a cerebrovascular accident or transient ischemic neurological attack (TIA) within the past six months,\n21. Subject has extensive peripheral vascular disease that precludes safe 6 French sheath insertion via any vessel.\n22. Subject has life expectancy \\\u003C 3 years.\n23. Subject is in the opinion of the Investigator or designee, unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason.\n24. Subject is currently participating in another clinical trial that has not yet completed its primary endpoint.\n25. Subject whose willingness to volunteer in a clinical investigation could be unduly influenced by the expectation, whether justified or not, of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate (e.g., subordinate hospital staff or sponsor staff).",{"count":117,"type":22},50,[25],"A Clinical Evaluation of AMJ-401 in the Treatment of Subjects with Ischemic Heart Disease in Japan",[28],"2026-04-06",{"date":123,"type":39},"2026-04-07",{"date":125,"type":39},"2025-12-17",{"date":127,"type":22},"2031-10-31",{"name":129,"class":130},"Abbott Medical Devices","INDUSTRY",10,{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":138,"sex":17,"minAge":139,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":78},"100519705","prognostic-value-of-hyperpolarized-13c-mri-for-clinical-myocardial-viability-100519705","NCT06047028","Prognostic Value of Hyperpolarized 13C MRI for Clinical Myocardial Viability","The eligibility criteria for this feasibility study are designed to select participants who will provide valuable insights into myocardial metabolism using HP-13C MRI in various contexts related to ischemic heart failure. These criteria aim to ensure that the study population is diverse and representative of the patient groups under investigation.\n\nInclusion\u002FExclusion Criteria:\n\n* Age range: 20 to 80 years\n* Sex: Random allocation\n* Left ventricular ejection fraction (LVEF):\n* Preoperative patients with LVEF \\\u003C 0.35\n* Healthy subjects with LVEF \\> 0.50\n* Clinical history:\n* Previous myocardial infarction (MI): Excluded for healthy subjects, included for preoperative patients.\n* Diabetes mellitus: Excluded for all participants.\n* Hypertension: Included for all participants\n* Mean blood pressure: Systolic \\\u003C 140 mm Hg and Diastolic \\\u003C 90 mm Hg for all participants\n* Mean heart rate: 78 beats\u002Fmin for all participants\n* Current smoker status: Included but will be reported.\n* Medication use within 24 hours: Use will be reported.\n* Coronary artery bypass surgery history: Excluded for healthy subjects, included for preoperative patients.\n* Infarct type and location: Excluded for healthy subjects, included for preoperative patients with various Q-wave infarct types and locations.\n* Number of diseased coronary vessels: Excluded for healthy subjects, included for preoperative patients with at least one diseased vessel.\n* Additional medical history and clinical data: Variations in data availability are expected based on the practices of referring physicians and will be documented.",true,"20 Years","80 Years",{"count":88,"type":22},"Heart failure due to coronary artery disease represents a significant cause of mortality. The detection of patients eligible for bypass surgery is a pivotal concern. Nevertheless, the optimal approach for patient selection based on conventional imaging scans remains unclear. The proposed method (Hyperpolarized 13C MRI) has gained extensive use in evaluating in vivo metabolism. This method avoids ionizing radiation and provides critical insights into cardiac function. The feasibility study aims to investigate this method for patient selection before bypass surgery. This innovative imaging technique facilitates the identification of two simple molecules, bicarbonate and lactic acid, produced at high rates by normal heart metabolism. Both bicarbonate and lactate originate from the same precursor molecule, pyruvate. The data generated from this study holds the potential to refine diagnostic precision.",[144,28,145],"Coronary Artery Disease","Myocardial Viability",[147,148,149,150],"Hyperpolarized 13C MRI","Coronary Artery Bypass Surgery","Segmental myocardial metabolism","Mitochondrial function","2026-02-24",{"date":153,"type":39},"2026-02-27",{"date":155,"type":39},"2023-06-30",{"date":157,"type":22},"2026-06-30",{"name":159,"class":46},"University of Texas Southwestern Medical Center",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":78},"100619992","cmr-prognostic-markers-in-ischemic-heart-disease-100619992","NCT07351825","CMR Prognostic Markers in Ischemic Heart Disease","Prognostic Value of Multiparametric Cardiovascular Magnetic Resonance in Patients With Ischemic Heart Disease: A Multicenter Retrospective Cohort Study","Inclusion Criteria:\n\n1. Adults (≥18 years of age).\n2. Patients with ischemic heart disease, including prior or recent myocardial infarction, who underwent clinically indicated cardiac magnetic resonance (CMR) imaging.\n3. Availability of analyzable CMR images, including but not limited to cine imaging, late gadolinium enhancement (LGE), and parametric mapping sequences (T1 and\u002For T2 mapping), as applicable.\n4. Availability of baseline clinical data and longitudinal follow-up information.\n\nExclusion Criteria:\n\n1. Poor image quality or incomplete CMR data precluding quantitative analysis.\n2. Presence of other severe comorbid conditions expected to significantly affect survival or clinical outcomes.\n3. Missing key clinical outcome data during follow-up.",{"count":21,"type":22},"Ischemic heart disease (IHD) remains a leading cause of morbidity and mortality worldwide. Accurate risk stratification is essential for guiding clinical management and improving long-term outcomes in patients with ischemic myocardial injury.\n\nCardiovascular magnetic resonance (CMR) imaging provides comprehensive assessment of myocardial structure, function, and tissue characteristics, enabling detailed evaluation of ischemic injury and its consequences.\n\nThis multicenter, retrospective observational study aims to investigate the prognostic value of multiparametric CMR-derived imaging markers in patients with ischemic heart disease who underwent clinically indicated CMR examinations. Imaging parameters of interest include late gadolinium enhancement (LGE), infarct size, microvascular obstruction (MVO), left ventricular and left atrial strain, and native T1 and T2 mapping values.\n\nLong-term clinical outcomes will be obtained from existing medical records. The primary outcome is major adverse cardiovascular and cerebrovascular events (MACCE), and secondary outcome is cardiovascular death. This study seeks to clarify the role of CMR in long-term risk stratification of patients with ischemic heart disease.",[28,170],"Myocardial Infarction (MI)",[172,173,174,175,176,177],"Ischemic heart disease","Cardiovascular magnetic resonance","Late gadolinium enhancement","Radiomics","Risk stratification","Prognosis","2026-01-11",{"date":180,"type":39},"2026-01-20",{"date":182,"type":39},"2009-01",{"date":184,"type":22},"2035-12",{"name":186,"class":46},"Chinese Academy of Medical Sciences, Fuwai Hospital"]